iCAD, Inc.

289 articles with iCAD, Inc.

• iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval

  6/14/2021

  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis received CE Mark approval.

• iCAD Signs Global Distribution Agreement with Sectra

  6/8/2021

  Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide

• iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

  5/17/2021

  Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

• iCAD Reports Financial Results for First Quarter Ended March 31, 2021

  4/28/2021

  First Quarter Revenues of $8.6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue

• iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28

  4/20/2021

  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28. Wednesday April 28th @ 4:30pm ET

• New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists’ Workflow

  4/19/2021

  Studies presented at two leading breast imaging conferences demonstrate ProFound AI helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

• iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

  4/5/2021

  Company expects preliminary estimated revenues to exceed $8.1 million Successor CFO search underway

• New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates

  3/31/2021

  Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions

• iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography

  3/15/2021

  Company’s third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software Deep learning technology builds upon iCAD’s established leadership in mammography AI

• iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock - Mar 03, 2021

  3/3/2021

  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per share.

• iCAD Announces Proposed Public Offering of Common Stock - Mar 02, 2021

  3/2/2021

  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020

  2/24/2021

  Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue

• iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24

  2/18/2021

  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will release financial results for the fourth quarter and year ended December 31, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, February 24.

• iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  2/16/2021

  iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18 th at 4:30pm ET

• iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access EventNew ProFound AI risk software, offering a 2-year projected risk score to be featured

  1/6/2021

  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

• Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

  12/10/2020

  iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography , the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI)

• iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution

  12/3/2020

  Leading Clinical Experts Discuss Advancing Personalized Breast Cancer Screening and Detection with Newly Launched ProFound AI Risk Added Market Growth Opportunit y Presented by Pioneering AI Breast Cancer Risk Offering Webinar Taking Place on Monday, December 7 @ 11am ET

• iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

  11/30/2020

  iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions , including the expanded ProFound AI ® platform powered by Panorama, at the 106 th Scientific Assembly and virtual Annual Meeting of the Radiological Society of North America (RSNA), November 29 – December 5. The Company’s full sui

• iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

  11/24/2020

  Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji

• iCAD Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020

  11/5/2020

  Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively